[1] |
DISTEFANO JK. NAFLD and NASH in postmenopausal women: Implications for diagnosis and treatment[J]. Endocrinology, 2020, 161( 10): bqaa134. DOI: 10.1210/endocr/bqaa134.
|
[2] |
BENCE KK, BIRNBAUM MJ. Metabolic drivers of non-alcoholic fatty liver disease[J]. Mol Metab, 2021, 50: 101143. DOI: 10.1016/j.molmet.2020.101143.
|
[3] |
KLAIR JS, YANG JD, ABDELMALEK MF, et al. A longer duration of estrogen deficiency increases fibrosis risk among postmenopausal women with nonalcoholic fatty liver disease[J]. Hepatology, 2016, 64( 1): 85- 91. DOI: 10.1002/hep.28514.
|
[4] |
Menopausal Group of Obstetrics and Gynecology Branch of Chinese Medical Association. The 2023 Chinese menopause symptom management and menopausal hormone therapy guidelines[J]. Chin J Obstet Gynecol, 2023, 58( 1): 4- 21. DOI: 10.3760/cma.j.cn112141-20221118-00706.
中华医学会妇产科学分会绝经学组. 中国绝经管理与绝经激素治疗指南2023版[J]. 中华妇产科杂志, 2023, 58( 1): 4- 21. DOI: 10.3760/cma.j.cn112141-20221118-00706.
|
[5] |
National Workshop on Fatty Liver and Alcoholic Liver Disease, Chinese Society of Hepatology, Chinese Medical Association; Fatty Liver Expert Committee, Chinese Medical Doctor Association. Guidelines of prevention and treatment for nonalcoholic fatty liver disease: A 2018 update[J]. J Clin Hepatol, 2018, 34( 5): 947- 957. DOI: 10.3969/j.issn.1001-5256.2018.05.007.
中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会. 非酒精性脂肪性肝病防治指南(2018年更新版)[J]. 临床肝胆病杂志, 2018, 34( 5): 947- 957. DOI: 10.3969/j.issn.1001-5256.2018.05.007.
|
[6] |
Liver Disease Committee, Chinese Association of Integrative Medicine. Guidelines for the diagnosis and treatment of liver fibrosis in integrative medicine practice(2019)[J]. J Clin Hepatol, 2019, 35( 7): 1444- 1449. DOI: 10.3969/j.issn.1001-5256.2019.07.007.
中国中西医结合学会肝病专业委员会. 肝纤维化中西医结合诊疗指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35( 7): 1444- 1449. DOI: 10.3969/j.issn.1001-5256.2019.07.007.
|
[7] |
EDDOWES PJ, SASSO M, ALLISON M, et al. Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease[J]. Gastroenterology, 2019, 156( 6): 1717- 1730. DOI: 10.1053/j.gastro.2019.01.042.
|
[8] |
YOUNOSSI ZM, KOENIG AB, WYMER M, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes[J]. Hepatology, 2016, 64( 1): 73- 84. DOI: 10.1002/hep.28431.
|
[9] |
ROBEVA R, MLADENOVIĆ D, VESKOVIĆ M, et al. The interplay between metabolic dysregulations and non-alcoholic fatty liver disease in women after menopause[J]. Maturitas, 2021, 151: 22- 30. DOI: 10.1016/j.maturitas.2021.06.012.
|
[10] |
LOBO RA, GOMPEL A. Management of menopause: A view towards prevention[J]. Lancet Diabetes Endocrinol, 2022, 10( 6): 457- 470. DOI: 10.1016/S2213-8587(21)00269-2.
|
[11] |
GEORGIOPOULOS G, KONTOGIANNIS C, STAKOS D, et al. Abdominal fat tissue echogenicity: A marker of morbid obesity[J]. J Clin Endocrinol Metab, 2019, 104( 2): 301- 311. DOI: 10.1210/jc.2018-01301.
|
[12] |
JEONG HG, PARK H. Metabolic disorders in menopause[J]. Metabolites, 2022, 12( 10): 954. DOI: 10.3390/metabo12100954.
|
[13] |
WANG XY, WANG LH, DI JL, et al. Prevalence and risk factors for menopausal symptoms in middle-aged Chinese women: A community-based cross-sectional study[J]. Menopause, 2021, 28( 11): 1271- 1278. DOI: 10.1097/GME.0000000000001850.
|
[14] |
WU YJ, ZHANG WS, ZHU F, et al. Correlation between natural menopause age and postmenopausal metabolic syndrome[J]. Chin J Prev Med, 2023, 57( 3): 433- 437. DOI: 10.3760/cma.j.cn112150-20220601-00560.
吴永君, 张维森, 朱峰, 等. 自然绝经年龄与绝经后代谢综合征的相关性研究[J]. 中华预防医学杂志, 2023, 57( 3): 433- 437. DOI: 10.3760/cma.j.cn112150-20220601-00560.
|
[15] |
MENG X, LI SY, DUAN WH, et al. Secular trend of age at menarche in Chinese adolescents born from 1973 to 2004[J]. Pediatrics, 2017, 140( 2): e20170085. DOI: 10.1542/peds.2017-0085.
|
[16] |
WU ZY, XU YW, ZHANG LM. Correlation analysis of liver fibrosis with menopausal time and estrogen deficiency time in female patients with NAFLD[J]. Chin Hepatol, 2019, 24( 10): 1182- 1184. DOI: 10.14000/j.cnki.issn.1008-1704.2019.10.032.
吴宗妍, 徐优文, 张立梅. NAFLD女性患者肝纤维化与绝经时间和雌激素缺乏时间的相关性分析[J]. 肝脏, 2019, 24( 10): 1182- 1184. DOI: 10.14000/j.cnki.issn.1008-1704.2019.10.032.
|
[17] |
WEGERMANN K, GARRETT ME, ZHENG JY, et al. Sex and menopause modify the effect of single nucleotide polymorphism genotypes on fibrosis in NAFLD[J]. Hepatol Commun, 2021, 5( 4): 598- 607. DOI: 10.1002/hep4.1668.
|
[18] |
LEE YH, SON JY, KIM KS, et al. Estrogen deficiency potentiates thioacetamide-induced hepatic fibrosis in sprague-dawley rats[J]. Int J Mol Sci, 2019, 20( 15): 3709. DOI: 10.3390/ijms20153709.
|
[19] |
DOTLIC J, NICEVIC S, KURTAGIC I, et al. Hormonal therapy in menopausal transition: Implications for improvement of health-related quality of life[J]. Gynecol Endocrinol, 2020, 36( 4): 327- 332. DOI: 10.1080/09513590.2019.1676409.
|
[20] |
CAI XY, ZHANG ZJ. Pharmacological effects of phytoestrogens and research progress of related traditional Chinese medicine[J]. Res Pract Chin Med, 2020, 34( 2): 75- 78, 86. DOI: 10.13728/j.1673-6427.2020.02.015.
蔡心银, 张紫佳. 植物雌激素药理作用及相关中药的研究进展[J]. 现代中药研究与实践, 2020, 34( 2): 75- 78, 86. DOI: 10.13728/j.1673-6427.2020.02.015.
|
[1] | Yishan LIU, Lanting ZHANG, Yunyu ZHAO, Fanpu JI, Qinglei ZENG. Management of hepatitis C in children and pregnant women[J]. Journal of Clinical Hepatology, 2024, 40(4): 654-658. doi: 10.12449/JCH240402 |
[2] | Jing KUANG, Shuangqin TENG, Tongtong SHEN, Yiran YAN, Wei WANG, Chuan SHEN, Caiyan ZHAO. Risk factors for portopulmonary hypertension in liver cirrhosis and construction of a predictive model[J]. Journal of Clinical Hepatology, 2024, 40(9): 1802-1806. doi: 10.12449/JCH240914 |
[3] | Shanshan XU, Lixia QIU, Yali LIU, Jing ZHANG. Risk factors and predictive models for liver cancer after sustained virologic response in hepatitis C[J]. Journal of Clinical Hepatology, 2024, 40(6): 1259-1263. doi: 10.12449/JCH240629 |
[4] | Tianfu LIU, Liang WANG, Lingyi ZHANG. Risk factors for non-neoplastic portal vein thrombosis in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2023, 39(9): 2122-2127. doi: 10.3969/j.issn.1001-5256.2023.09.014 |
[5] | Gong FENG, Juanjuan SONG, Feng YE, Yonghong MA, Yilin REN, Ziyi ZHANG, Na HE, Xueping LI, Man MI. Recompensation of liver cirrhosis: Current status and challenges[J]. Journal of Clinical Hepatology, 2023, 39(10): 2464-2469. doi: 10.3969/j.issn.1001-5256.2023.10.027 |
[6] | Bingbing ZHU, Jinxiang YANG, Qun ZHANG, Fangyuan GAO, Xianbo WANG. Risk factors for the 90-day prognosis of patients with type I hepatorenal syndrome and establishment of a predictive model[J]. Journal of Clinical Hepatology, 2022, 38(7): 1561-1565. doi: 10.3969/j.issn.1001-5256.2022.07.019 |
[7] | Siqin LIU, Xiaomei WANG, Xia LI, Luwen LIANG, Ke WANG, Rui WANG. Covert hepatic encephalopathy in liver cirrhosis: Risk factors and prognosis[J]. Journal of Clinical Hepatology, 2022, 38(2): 359-364. doi: 10.3969/j.issn.1001-5256.2022.02.020 |
[8] | Jiajia RUAN, Shifei WEN, Xia WANG, Li LI, Juanjuan FU, Xiucheng PAN. Influencing factors for recompensation in patients with first-time decompensated hepatitis B cirrhosis[J]. Journal of Clinical Hepatology, 2022, 38(8): 1796-1800. doi: 10.3969/j.issn.1001-5256.2022.08.015 |
[9] | Zhiying HE, Bingqiong WANG, Hong YOU. Liver cirrhosis: Decompensation and "recompensation"[J]. Journal of Clinical Hepatology, 2022, 38(5): 1002-1005. doi: 10.3969/j.issn.1001-5256.2022.05.006 |
[10] | Shanshan LI, Manman XU, Zhongping DUAN, Yu CHEN. Risk factors for liver cirrhosis in acute-on-chronic liver failure patients without liver cirrhosis in the convalescence stage[J]. Journal of Clinical Hepatology, 2021, 37(12): 2824-2829. doi: 10.3969/j.issn.1001-5256.2021.12.019 |
[11] | LI ZhengHong, DONG YuWei, LU LunGen. Risk factors,diagnosis,and updated classification of hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2020, 36(11): 2411-2414. doi: 10.3969/j.issn.1001-5256.2020.11.003 |
[12] | Ruan FangMing, Li BiMin. Risk factors for the formation of portal vein thrombosis in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2020, 36(1): 182-185. doi: 10.3969/j.issn.1001-5256.2020.01.043 |
[13] | Lyu Jing, Dong SiSi, Gu HongTu, Zhao ZhangQing, Liu ChengHai. TCM syndrome characteristics of portal vein thrombosis in patients with liver cirrhosis and related risk factors[J]. Journal of Clinical Hepatology, 2019, 35(10): 2210-2213. doi: 10.3969/j.issn.1001-5256.2019.10.016 |
[14] | He Yang, Su YaRong, Han ZiYan. Current status of research on primary and secondary risk factors for esophagogastric variceal rebleeding in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2018, 34(7): 1555-1559. doi: 10.3969/j.issn.1001-5256.2018.07.041 |
[15] | Jin Yan, Wang Xue, Zhang LingJuan, Qiu Ting, Shang BoXin, Lian XiaoYan, Yan ChunYing, Duan TianJiao, Zhang Rong, Liu GuiSheng. Risk factors for early rebleeding after esophageal variceal ligation in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2017, 33(11): 2147-2151. doi: 10.3969/j.issn.1001-5256.2017.11.019 |
[16] | Yu ZhiRui, Wei GuoXi, Liu QiChang, Jin PeiMin. Risk factors for HBV-related liver cirrhosis complicated by acute upper gastrointestinal bleeding[J]. Journal of Clinical Hepatology, 2017, 33(5): 860-863. doi: 10.3969/j.issn.1001-5256.2017.05.013 |
[17] | Zhou RenHua, Li Peng, Zhang YanTing, Yang Hua, Yang ShaoQi. Clinical manifestations of portal vein thrombosis and related risk factors in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2016, 32(2): 275-278. doi: 10.3969/j.issn.1001-5256.2016.02.015 |
[18] | Yang Hua, Liu YunXia, Li Peng, Yang ShaoQi, Wang YuanZhen. Analysis of risk factors for early rebleeding from esophageal and gastric varices in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2014, 30(6): 540-542. doi: 10.3969/j.issn.1001-5256.2014.06.015 |
[19] | Wang Hong. Risk factors for patients with cirrhosis developed renal dysfunction[J]. Journal of Clinical Hepatology, 2004, 20(2): 101-102. |